Last reviewed · How we verify
SB-681323 oral tablets
At a glance
| Generic name | SB-681323 oral tablets |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SB-681323-Methotrexate Interaction Study (PHASE1)
- Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-681323 oral tablets CI brief — competitive landscape report
- SB-681323 oral tablets updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI